Ermer

Method Validation in Pharmaceu

Herausgegeben von Ermer, Joachim; Nethercote, Phil W.

• Gebundenes Buch

Produktbeschreibung

The second edition of the best-selling practical guide to pharmaceutical analytics has been completely redesigned to take account of the Quality by Design (QbD) concept that has become the gold standard in pharmaceutical manufacturing. Two real-life case studies are included.

---

This second edition of a global best-seller has been completely redesigned and extensively rewritten to take into account the new Quality by Design (QbD) concept in pharmaceutical manufacturing.
As in the first edition, the analytical requirements during the entire product lifecycle are covered, but now a new section is included on continued performance monitoring and the transfer of analytical procedures. Two case studies from the pharmaceutical industry illustrate the concepts and guidelines presented, and the standards and regulations from the US (FDA), European (EMA) and global (ICH) regulatory authorities are considered throughout.
The undisputed gold standard in the field.

Produktdetails

• Verlag: Wiley-VCH
• Artikelnr. des Verlages: 1133563 000
• 2. Aufl.
• Seitenzahl: 436
• Erscheinungstermin: Oktober 2014
• Englisch
• Abmessung: 250mm x 175mm x 28mm
• Gewicht: 1095g
• ISBN-13: 9783527335633
• ISBN-10: 3527335633
• Artikelnr.: 40772353

Autorenporträt

Joachim Ermer is Head of Quality Control Services Chemistry at Sanofi in Frankfurt, Germany, and Global Reference Standards Coordinator of Sanofi. He studied biochemistry at University of Halle, Germany, and obtained a PhD in enzyme kinetics in 1988. He has more than 20 years of experience in pharmaceutical analytics including development projects, global responsibilities as Director of Analytical Processes and Technology, and Head of Quality Control. He is member of the USP Expert Panel on Validation and Verification, of the EFPIA Quality by Design Working Group, and of the Focus Group Analytics and Quality Assurance of the International Association of Pharmaceutical Technology (APV). From 2000 till 2008, he was Deputy Head of the Working Group Quality Control / Pharmaceutical Analytics of the German Pharmaceutical Society (DPhG). His special interest has been focused early on analytical validation and related topics, such as performance evaluation, statistics, and transfer of analytical procedures.. Phil Nethercote is the Analytical Head and API Analytical Lead for the Global Manufacturing and Supply division of GSK. He has a degree in chemistry from Herriot Watt University in Edinburgh and obtained a PhD in HPLC retention mechanisms from the University of Stirling in 1987. He is a Chartered Chemist and a member of the Royal Society of Chemistry. He has over 25 years of experience in the pharmaceutical industry the majority of which has been with Glaxo, Glaxo Wellcome and GSK where he has led analytical development and new product introduction teams in the UK and in Singapore. In his current role he provides leadership for analytical systems, processes and standards across GSKs global network of manufacturing sites. He is member of the USP Expert Panel on Validation and Verification, of the EFPIA Analytical Quality by Design Working Group and led the revision of the analytical section of the second edition of the ISPE technology transfer guide He has a passion for ensuring efforts invested in Analytical Method Validation and Transfer add real value in ensuring the methods produce fit for purpose data and has been a strong advocate in applying QbD principles to help achieve that aim.

Inhaltsangabe

Foreword ANALYTICAL VALIDATION WITHIN THE PHARMACEUTICAL LIFECYCLE
Development of Process and Analytical Validation Concepts Alignment between
Process and Analytics: Three-Stage Approach Predefined Objectives:
Analytical Target Profile Analytical Life Cycle ANALYTICAL INSTRUMENT
QUALIFICATION Analytical Instrument and System Qualification Efficient and
Economic HPLC Performance Qualification ESTABLISHMENT OF MEASUREMENT
REQUIREMENTS - ANALYTICAL TARGET PROFILE AND DECISION RULES Introduction
Defining the Fitness for Intended Use Decision Rules Overview of Process to
Develop Requirements for Procedure Performance Decision Rules and
Compliance Calculating Target Measurement Uncertainty Types of Decision
Rules Target Measurement Uncertainty in the Analytical Target Profile Bias
and Uncertainty in a Procedure ATP and Key Performance Indicators
Measurement Uncertainty Example Conclusion ESTABLISHMENT OF MEASUREMENT
REQUIREMENTS - PERFORMANCE-BASED SPECIFICATION Introduction Intended
Purpose Identification Assay Impurities Limit Tests Quantitative Tests
Summary METHOD PERFORMANCE CHARACTERISTICS Introduction Precision Accuracy
and Range Specificity Linearity Detection and Quantitation Limit Glossary
METHOD DESIGN AND UNDERSTANDING Introduction Analytical Quality by Design
and Robustness Investigations Case Study: Robustness Investigations System
Suitability Tests METHOD PERFORMANCE QUALIFICATION Introduction Case Study:
Qualification of an HPLCMethod for Identity, Assay, and Degradation
Products Design and Qualification of a Delivered Dose Uniformity Procedure
for a Pressurized Metered Dose Inhaler Implementation of
Compendial/Pharmacopeia Test Procedures Transfer of Analytical Procedures
CONTINUED METHOD PERFORMANCE VERIFICATION Introduction Routine Monitoring
Investigating and Addressing Aberrant Data Continual Improvement Index